Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline...
Transcript of Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline...
![Page 1: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/1.jpg)
Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC) : <br />A randomized, controlled, multicenter phase III trial of the<br /> Dutch Pancreatic Cancer Group
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 2: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/2.jpg)
Rationale
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 3: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/3.jpg)
Trial design
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 4: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/4.jpg)
Trial design
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 5: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/5.jpg)
Accrual
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 6: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/6.jpg)
baseline characteristics
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 7: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/7.jpg)
Results
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 8: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/8.jpg)
Overall survival (ITT)
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 9: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/9.jpg)
Disease free survival
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 10: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/10.jpg)
Metastases and local recurrence (ITT)
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 11: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/11.jpg)
Subset analysis
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 12: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/12.jpg)
Conclusion
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting
![Page 13: Presented By Geertjan Van Tienhoven at 2018 ASCO ......Geertjan van Tienhoven, AMC baseline characteristics Preop. Radiochemotherapy n=119 65 (33-80) Median age (range) WHO PS 0-1](https://reader034.fdocuments.us/reader034/viewer/2022042312/5edb4390ad6a402d66656384/html5/thumbnails/13.jpg)
Acknowledgements
Presented By Geertjan Van Tienhoven at 2018 ASCO Annual Meeting